Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

ARTICLE 2
GRANT OF RIGHTS

 

2.1.       Grants to Lilly. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, ACI (on behalf of itself and its Affiliates) hereby grants to Lilly:

 

2.1.1.       an exclusive (including with regard to ACI and its Affiliates) and non-transferable (except in accordance with Section ‎13.3) license (or sublicense), with the right to grant sublicenses in accordance with Section ‎2.3.1, under the ACI Patents, the ACI Know-How, and ACI’s interests in the Joint Patents and the Joint Know-How, in each case to Exploit the Licensed Compound and Licensed Products in the Field in the Territory[*****]; and

 

2.1.2.       a non-exclusive license, with the right to grant sublicenses in accordance with Section ‎2.3.1, to use ACI’s Corporate Names to the extent required under Section ‎4.5.

 

2.2.       Grants to ACI. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, Lilly hereby grants to ACI:

 

2.2.1.       a non-exclusive, royalty-free, non-transferable (except in accordance with Section ‎13.3) license, with the right to grant sublicenses in accordance with Section ‎2.3.2, under the Lilly Patents, the Lilly Know-How, and Lilly’s interests in the Joint Patents and the Joint Know-How, to (i) Develop Licensed Products in the Territory in accordance with the ACI Pre-Clinical and Phase 1 Activities and any other obligations set forth in the Development Plan, (ii) conduct the Unilateral Activities and (iii) Manufacture (or have Manufactured) Licensed Products in the Territory in accordance with the ACI Pre-Clinical and Phase 1 Activities and any of its other obligations as set forth in the Development Plan and Article 6; and

 

19 


© AC Immune 2015